Around 20% of breast cancers overexpress HER2, a potent tumor driver. In addition to HER2, a subpopulation of these cancers – approximately 35% – also present a variant known as p95HER2. Joaquin Arribas’ team has developed a novel immunotherapy against p95HER2 breast cancer. p95HER2-TCB is a T-Cell Bispecific antibody (TCB) that specifically binds to tumor cells expressing p95HER2 while recruiting T-cells to trigger an anti-tumor response from the patients’ immune system. The PRODUCTE grant will support the initial validation of p95HER2-TCB in in vivo Humanized Patient-Derived Xenograft models (HuPDX), which consists of reconstituting the human immune system in PDX-bearing immunodeficient mice.

Grup de Oncología Molecular

Randomized, open-label, phase2 study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SA240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage I-NEOPARP – Sanofi Aventis